What insurance policy changes affect CPT 96420?

There are 6 tracked policy changes affecting CPT 96420, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 96420?

Payers that have issued tracked updates for CPT 96420 include: Aetna.

How do I get notified when CPT 96420 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 96420. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 96420?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

96420 — A chemotherapy drug is injected directly into a vein as a single, quick push rather than a slow drip.: Insurance Policy Changes

96420 Insurance Policy Changes

CPT 96420, in plain terms, covers A chemotherapy drug is injected directly into a vein as a single, quick push rather than a slow drip. CPT 96420 is referenced in 6 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 96420 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

Tagraxofusp-erzs (Elzonris) (CPB 0947, reviewed 2026-05-28)

Aetna·Effective May 28, 2026

Aetna updated its coverage policy for Tagraxofusp-erzs (Elzonris) effective May 28, 2026, establishing medical necessity coverage for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) as a single agent in commercial plans. The policy specifies dosing (12 mcg/kg IV daily days 1-5 of 21-day cycles), first-cycle inpatient administration requirement, and continuation criteria based on tolerability and disease response. All other indications remain experimental/investigational.

96420 Insurance Policy Changes

Fam-trastuzumab Deruxtecan-nxki (Enhertu) (CPB 0966, reviewed 2026-05-15)

Liver and Other Neoplasms - Treatment Approaches (CPB 0268, reviewed 2026-04-16)

Oxaliplatin (CPB 0683, reviewed 2025-12-05)

Tagraxofusp-erzs (Elzonris) (CPB 0947, reviewed 2026-05-28)

Liver and Other Neoplasms - Treatment Approaches (CPB 0268, reviewed 2026-09-18)

Ziv-Aflibercept (Zaltrap) (CPB 0842, reviewed 2025-12-09)